Generic Oncology Sterile Injectables Market
According to Intent Market Research, the Generic Oncology Sterile Injectables Market is expected to grow from USD 8.3 billion in 2023 at a CAGR of 7.1% to touch USD 13.5 billion by 2030. The Generic Oncology Sterile Injectables Market is dominated by key players such as, Teva Pharmaceutical Industries Ltd., Sandoz (Novartis), Dr. Reddy–s Laboratories, Hikma Pharmaceuticals PLC, and Sun Pharmaceutical Industries Ltd.